Compare TDOC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | KURA |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 841.6M |
| IPO Year | 2015 | 2015 |
| Metric | TDOC | KURA |
|---|---|---|
| Price | $6.58 | $11.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 11 |
| Target Price | $7.56 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | $67,482,000.00 |
| Revenue This Year | $1.19 | $28.28 |
| Revenue Next Year | $1.25 | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.41 | ★ 25.24 |
| 52 Week Low | $4.40 | $5.45 |
| 52 Week High | $9.77 | $12.49 |
| Indicator | TDOC | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 70.82 |
| Support Level | $6.42 | $8.80 |
| Resistance Level | $7.95 | $11.17 |
| Average True Range (ATR) | 0.32 | 0.59 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 28.76 | 86.05 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.